# Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

> **NCT04683965** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 27 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** TAS-102
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04683965
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683965, "Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04683965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*